Amidst high-profile deals like Pfizer's pursuit of AstraZeneca, Actavis's acquisition of Forest Labs, and Valeant's (NYSE: VRX ) pursuit of Allergan,
it might be easy to forget that it is not just large companies that can
benefit from tax inversion deals that lead to a company reestablishing
its headquarters in a lower-tax jurisdiction. Auxilium (NASDAQ: AUXL )
, a small specialty pharmaceutical company, has thrown its hat into the
tax inversion ring with an announced acquisition of Canada's QLT (NASDAQ: QLTI )
. Investors did not universally cheer the news, though, and it's
unclear just how much benefit Auxilium will really see from this move.
Read more here:
Auxilium Pharmaceuticals Inc Joins the Buyout Bonanza
No comments:
Post a Comment